Alpha Layer / Signal Explorer

Signal Explorer

10-K · 10-Q · 8-K · last 6 months · ← back to feed

Clear ×
COGNITION THERAPEUTICS INC CGTX

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Oct 22, 2026 8-K 10 signals fired
Core
Secondary Endpoint Mentioned Clinical Hold Clinical Trial Result Indication Expansion
Other
Fda Aligned Protocol Amended Interim Data Positive Publication Positive Enrollment Ahead Of Schedule
Biotech Risk
Trial Endpoint Missed
Aug 7, 2026 10-Q 17 signals fired · top 15
Other
Rsu Psu Vesting Schedule Disclosed Net Loss Reported Financing Activities Cash Flow Disclosure Warrant Valued Black Scholes Personnel Cost Decrease Disclosure Valuation Allowance Deferred Tax Disclosure Fda Aligned Material Weakness Internal Controls Interim Data Positive Tenant Restoration Obligation Ipo Or Capital Raising Completion Coso Icfr Assessment Disclosure Administrative Efficiency
Core
Clinical Trial Result Secondary Endpoint Mentioned
Aug 6, 2026 8-K 6 signals fired
Other
Liquidity Position Snapshot Disclosed Personnel Cost Decrease Disclosure Revenue Increase Attribution Disclosure
Core
Lead Asset Progress Clinical Hold
Biotech Risk
Clinical Hold Active
Jun 24, 2026 8-K 19 signals fired · top 15
Core
Clinical Trial Result Lead Asset Progress Secondary Endpoint Mentioned Clinical Hold
Other
Interim Data Positive Fast Track Granted Fast Track Designation Received Fda Aligned Orphan Status Granted Publication Positive Expanded Access Program Active Enrollment Ahead Of Schedule
Biotech Risk
Trial Endpoint Missed Clinical Hold Active Orphan Drug Designation
Jun 18, 2026 8-K 0 signals fired
No signals above threshold for this filing.
Jun 4, 2026 8-K 11 signals fired
Other
Forward Looking Statement Definition Interim Data Positive Fast Track Granted Ceo Team Pride Statement Enrollment Ahead Of Schedule Publication Positive Orphan Status Granted Safety Differentiated
Core
Clinical Trial Result Lead Asset Progress Combination Therapy Mentioned
May 21, 2026 8-K 6 signals fired
Core
Clinical Trial Result Lead Asset Progress Secondary Endpoint Mentioned Combination Therapy Mentioned
Other
Interim Data Positive
Biotech Risk
Crl Received
May 8, 2026 10-Q 31 signals fired · top 15
Other
Rsu Psu Vesting Schedule Disclosed Net Loss Reported Cash Flow Statement Investing Activities Financing Activities Cash Flow Disclosure Personnel Cost Decrease Disclosure Valuation Allowance Deferred Tax Disclosure Equity Plan Share Reserve Disclosure Expanded Access Program Active Other Income Expense Disclosure Enrollment Ahead Of Schedule Interim Data Positive Segment Aggregation Disclosure Burn Rate Controlled
Core
Clinical Trial Result Secondary Endpoint Mentioned
May 7, 2026 8-K 6 signals fired
Other
Liquidity Position Snapshot Disclosed Personnel Cost Decrease Disclosure Administrative Efficiency Interim Data Positive
Core
Clinical Trial Result Indication Expansion